Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Gerald Hsu

Lymphoma · UCSF

View

Dr. Chadi Nabhan

Lymphoma · Ryght AI / USC

View

Dr. Jonathan Friedberg

Lymphoma · URMC

View

Dr. Matthew Matasar

Lymphoma · Rutgers Cancer Institute

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MRDr. Mark Roschewski
    Leading Voice

    Dr. Mark Roschewski

    Hematology & Oncology · Lymphoma
    Memorial Sloan Kettering Cancer Center
    markr

    Research

    When will circulating tumor DNA be ready for prime time in lymphoma?

    2026

    Via Clinical Advances in Hematology & Oncology

    Research

    Axes of biological variation in diffuse large B cell lymphoma.

    2026

    Via Cancer Cell

    Research

    SOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas.

    2026

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Minimal residual disease guided treatment approaches in non-Hodgkin lymphoma—Where we are and where we're headed.

    2026

    Via Seminars in Hematology

    Research

    A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

    2026

    Via Blood Advances

    Research

    An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors.

    2025

    Via ACS Pharmacology & Translational Science

    Research

    Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent

    2025

    Via Liver International

    Research

    Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma: A Narrative Review

    2025

    Via JAMA Oncology

    Research

    Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas

    2025

    Via Leukemia & Lymphoma

    Research

    The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas

    2025

    Via British Journal of Haematology

    Research

    Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma

    2025

    Via British Journal of Haematology

    Research

    Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

    2025

    Via Journal of Clinical Oncology

    Research

    Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.

    2024

    Via Blood Advances

    Research

    Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy

    2024

    Via Haematologica

    Research

    Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas

    2024

    Via Blood Advances